Prudential Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Prudential Financial’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,592	Closed	-$2.32M	–	2759
2023 Q1	$2.32M	Buy	21,592 +1,095	+5%	+$126K	﹤0.01%	1248
2022 Q4	$2.25M	Buy	+20,497	New	+$1.33M	﹤0.01%	1249

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Prudential Financial's RXDX Position: Q2 2023 in Review

Prudential Financial sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 21,592 shares — an estimated $2.32M sold.

Prudential Financial first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $2.32M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Prudential Financial reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Prudential Financial sold 21,592 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.32M.
Prudential Financial first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Prudential Financial's Prometheus Biosciences, Inc. Common Stock position peaked at $2.32M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Prudential Financial's 13F filing for Q2 2023, filed 11 Aug 2023.